Business
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted
About this update from Axsome Therapeutics, Inc.
[{"type":"image","alt":"Axsome Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Axsome Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/0ea606c97ef1ad84f216f58f2c804d3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zyuSg_zGs4BBxpNr3zq4FA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0ea606c97ef1ad84f216f58f2c804d3d","width":222,"height":125}},"lazy":false},{"type":"text","content":"NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Under the terms of the settlement agreement, Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on or after September 1, 2040, if pediatric exclusivity is granted for Sunosi, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.","length":1054,"tagName":"p"},{"type":"text","content":"As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by Axsome against other parties related to Sunosi remains pending in the U.S. District Court for the District of New Jersey.","length":316,"tagName":"p"},{"type":"text","content":"About Axsome Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mech...